ClinicalTrials.gg
CompletedNCT04495140Updated Nov 25, 2020

Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

A Phase 1 interventional study of [14C]PF-06882961, 50 mg and PF-06882961, 50 mg and [14C]PF-06882961, 100 ug in Healthy Volunteer, sponsored by Pfizer. Completed at 2 sites in Netherlands. Open to male participants aged 18 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-25.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Oct 2020, 6 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years to 54 Years
Sex
Male
01

Study summary

This study is a Phase 1, open-label, non-randomized, 2-period, fixed sequence study to characterize the metabolic profile and routes of excretion of oral [14C]PF-06882961 and to evaluate the absolute oral bioavailability of PF-06882961 and fraction absorbed of [14C]PF-06882961 in reference to intravenous [14C]PF-06882961 in healthy male participants.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • bioavailability
  • excretion
  • metabolism
  • absorption
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants between 18 to 54 years of age
  • Healthy and capable of signing document
  • Willing to comply to all scheduled visits, lab tests, lifestyle considerations and study procedures
  • (BMI) of 17.5 to 30 kg/m2; and a total body weight ≥50 kg (110 lb).

Exclusion criteria

Exclusion Criteria:

  • acute or chronic medical or psychiatric condition including recent (within the past year)
  • Surgical procedures like gastrectomy, cholecystectomy, Irregularity in bowel movements
  • Use of prescription or non-prescription drugs and dietary and herbal supplements within 14 days prior to the first dose of product.
  • Previous administration with an investigational drug within 60 days (or as determined by the local requirement) preceding the first dose of investigational product used in this study.
  • Known prior participation in a trial involving PF-06882961 or known intolerance to a GLP-1R agonist.
  • A positive urine drug test on screening or Day -1.
  • Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
  • Participants with abnormalities in clinical laboratory tests including ECGs, vital signs, liver function tests, myocardial infarction
  • Positive testing for (HIV), surface antigen (HBsAg), or antibody (HCVAb). Hepatitis B vaccination is allowed.
  • History of alcohol or tobacco abuse or binge drinking and/or any other illicit drug use or dependence within past 6 months.
  • Subjects whose occupation requires exposure to radiation or monitoring of radiation exposure.
  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia only if heparin is planned to flush intravenous catheters.
  • Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Oral [14C]PF-06882961, 50 mg

    In this arm, a single oral dose of \[14C\]PF-06882961, 50 mg will be administered as a liquid formulation.

    Drug: [14C]PF-06882961, 50 mg

  • Experimental
    Oral PF-06882961 50 mg and intravenous [14C]PF-06882961 100 ug

    In this arm, single oral dose of unlabeled PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961, 100 ug, will be administered via intravenous infusion.

    Drug: PF-06882961, 50 mg and [14C]PF-06882961, 100 ug

Interventions

  • A single oral dose of \[14C\]PF-06882961, will be administered as a liquid formulation.

  • DrugPF-06882961, 50 mg and [14C]PF-06882961, 100 ug

    Drug page: Danuglipron

    A single, oral, unlabeled dose of PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961 will be administered via intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Total recovery of radioactivity in urine and feces, following oral administration of [14C] PF-06882961 in period 1

    Total recovery of radioactivity in urine and feces, and both routes combined, expressed as a percent of total oral radioactive dose administered.

    Time frame: Baseline through approximately hour 312 (day 14). Period 1 is 14 days

Secondary outcomes

  1. Metabolite profiling/identification in plasma, urine, and feces

    Metabolic profiling/identification and determination of relative abundance of \[14C\]PF-06882961 and the metabolites of \[14C\]PF-06882961 in plasma, urine, and feces.

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96-312 hour (hr)

  2. Plasma Cmax to describe plasma PK of total radioactivity following administration of single, oral dose of [14C] PF-06882961

    Maximum Observed Plasma Radioactivity

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr

  3. Plasma Tmax to describe the PK of total radioactivity following administration of single, oral dose of [14C]PF-06882961

    Time to Reach Maximum Observed Plasma Radioactivity

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr

  4. Plasma AUClast to describe PK of total radioactivity following administration of single, oral dose of [14C] PF-06882961

    Area under the plasma radioactivity-time profile from time 0 to time of the last quantifiable concentration (Clast)

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr

  5. Plasma AUCinf to describe plasma PK of total radioactivity following administration of single, oral dose of [14C] PF-06882961

    AUCinf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr

  6. Plasma elimination t½ to describe plasma PK of total radioactivity following administration of single, oral dose of [14C] PF-06882961

    Plasma elimination half-life is the time measured for the plasma radioactivity to decrease by one half.

    Time frame: 00, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr

  7. Plasma Cmax to describe the plasma PK of PF-06882961 following administration of single, oral dose of [14C] PF-06882961

    Maximum Observed Plasma Concentration

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr

  8. Plasma Tmax to describe the plasma PK of PF-06882961 following administration of single, oral dose of [14C]PF-06882961

    Time to Reach Maximum Observed Plasma Concentration

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr

  9. Plasma AUClast to describe PK of PF-06882961 following administration of single, oral dose of [14C] PF-06882961

    Area under the plasma concentration-time profile from time 0 to time of the last quantifiable concentration (Clast)

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr

  10. Plasma AUCinf to describe plasma PK of PF-06882961 following administration of single, oral dose of [14C] PF-06882961

    AUCinf is Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr

  11. Mean residence Time (MRT )following administration of a single, intravenous dose of [14C]PF 06882961

    where MRT is the Mean Residence Time

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72 hr

  12. Systemic Clearance (CL) following administration of a single, intravenous dose of [14C]PF 06882961

    Systemic clearance, CL is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72 hr

  13. Volume of distribution at steady state (Vss) following administration of a single, intravenous dose of [14C]PF 06882961

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

    Time frame: 0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72 hr

  14. Absolute oral bioavailability (F)

    Absolute oral bioavailability following administration of a single oral dose of PF-06882961 in reference to a single intravenous dose of \[14C\]PF-06882961

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr

  15. Fraction of dose absorbed following single oral administration of [14C]PF-06882961

    Fraction absorbed calculated from ratio of total urinary radioactivity following oral administration in reference to intravenous administration

    Time frame: 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96-312hr

  16. Number of participants with adverse events

    adverse events

    Time frame: Baseline in Period 1 up to 32 days after the period 2 doses, for a total of approximately 46 days

  17. Plasma elimination t½ to describe plasma PK of PF-06882961 following administration of single, oral dose of [14C] PF-06882961

    Plasma elimination half-life is the time measured for the plasma radioactivity to decrease by one half.

    Time frame: 00, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr

  18. Number of participants with safety laboratory test results above/below certain threshold

    lab tests

    Time frame: baseline, day 5-14 of period 1 (period 1 is 14 days), day 3-8 of period 2 (period 2 is 8 days)

  19. Number of participants with ECG measurements above/below certain threshold

    ECGs

    Time frame: baseline, day 5-14 of period 1 (period 1 is 14 days), day 3-8 of period 2 (period 2 is 8 days)

  20. Number of participants with vital measurements above/below certain threshold

    vitals

    Time frame: baseline, day 5-14 of period 1 (period 1 is 14 days), day 3-8 of period 2 (period 2 is 8 days)

07

Study locations

2 sites
  • PRA Health Sciences
    Groningen, 9728 NZ, Netherlands
  • PRA Health Sciences Utrecht
    Utrecht, 3584 BL, Netherlands
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Oct 2020, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2020
First posted
Jul 31, 2020
StartActual
Jul 22, 2020
Primary completionActual
Oct 15, 2020
CompletionActual
Oct 15, 2020
Last update
Nov 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04495140
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 31, 2020
Start date
Jul 22, 2020
Primary completion
Oct 15, 2020
Completion
Oct 15, 2020
Last update
Nov 25, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danuglipron

Start the discussion